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Abstract 
It is commonly accepted that human immunodeficiency (HIV) coinfection negatively impacts on the rates of 
sustained virological response (SVR) to therapy with pegylated interferon plus ribavirin (PR). However, this 
hypothesis is derived from comparing different studies. The aim of this study was to determine the impact of 
HIV coinfection on SVR to PR in one single population. In a multicentric, prospective study conducted 
between 2000 and 2013, all previously naïve hepatitis C virus (HCV)-infected patients who started PR in five 
Spanish hospitals were analyzed. SVR was evaluated 24 weeks after the scheduled end of therapy. Of the 
1046 patients included in this study, 413 (39 %) were coinfected with HIV. Three hundred and forty-one 
(54 %) HCV-monoinfected versus 174 (42 %) HIV/HCV-coinfected patients achieved SVR (p < 0.001). The 
corresponding figures for undetectable HCV RNA at treatment week 4 were 86/181 (47 %) versus 59/197 
(30 %), p < 0.001. SVR was observed in 149 (69 %) HCV genotype 2/3-monoinfected subjects versus 91 
(68 %) HIV/HCV genotype 2/3-coinfected subjects (p = 0.785). In the HCV genotype 1/4-infected 
population, 188 (46 %) monoinfected patients versus 82 (30 %) with HIV coinfection (p < 0.001) achieved 
SVR. In this subgroup, absence of HIV coinfection was independently associated with higher SVR [adjusted 
odds ratio (95 % confidence interval): 2.127 (1.135–3.988); p = 0.019] in a multivariate analysis adjusted for 
age, sex, baseline HCV RNA load, IL28B genotype, fibrosis stage, and type of pegylated interferon. HIV 
coinfection impacts on the rates of SVR to PR only in HCV genotype 1/4-infected patients, while it has no 







Until a few years ago, standard-of-care treatment against hepatitis C virus (HCV) infection was 
dual therapy with pegylated interferon (Peg-IFN) plus ribavirin (RBV). Currently, this 
combination continues to be the backbone for some of the first-line recommended regimens. In 
addition, it is still recommended in settings where direct-acting antivirals (DAA) are not available 
due to financial restrictions [1]. Rates of sustained virological response (SVR) to Peg-IFN plus 
RBV vary considerably according to host and virus-related parameters, such as IL28B genotype, 
grade of liver damage, baseline plasma HCV RNA concentration, and HCV genotype [2, 3]. 
 
It is widely accepted that human immunodeficiency (HIV) coinfection has a negative impact 
on SVR rates. This belief is based on response rates reported by the Peg-IFN registration trials and 
several cohort studies, where SVR rates among genotype 1, 2/3, and 4 carriers were in the range 
42–46 %, 76–82 %, and 50–77 % in monoinfected patients [4, 5] and in the range 17–29 % and 
44–62 % in genotype 1/4 and 2/3 in HIV/HCV-coinfected patients [6, 7], respectively. However, 
these studies followed different protocols and were conducted in different centers and the results 
are, thus, not comparable. To date, there are little data available on the impact on HIV infection on 
SVR to dual therapy coming from studies carried out in the same hospitals, where patients are 
followed by the same clinicians with a common management protocol. 
 
Even though dual therapy has lost importance with the arrival of DAA, the evaluation of the 
role of HIV infection in the response to antiviral therapy is a crucial step to understanding the 
singularities of the HIV/HCV-coinfected population. Additionally, it may contribute to optimizing 
treatment strategies in the era of DAA, where the impact of HIV infection is little studied. 
 
The aim of this study was to determine the impact of HIV infection on the response to 
combination therapy with Peg-IFN plus RBV in a single population. 
Materials and Methods 
Study design 
This multicentric, prospective study was conducted between 2000 and 2013 at the infectious 
diseases units of five Spanish hospitals. Each hospital included all HCV-infected patients 
attending these units, regardless of whether they were HIV-coinfected or not, if the following 
criteria were met: (i) older than 18 years of age, (ii) naïve for HCV treatment, and (iii) started 
therapy with Peg-IFN plus RBV. Visits were scheduled at treatment week (TW) 0, 4, 12, and, 
when applicable, 24 and 48, as well as 24 weeks after the scheduled end of treatment in order to 
evaluate SVR. At each visit from TW12 onwards, HCV RNA levels were quantified and 
hematological parameters were determined. HCV RNA determinations at TW4 were included in 
the protocol after the identification of rapid virological response (RVR) as a predictor of response, 
and it is, therefore, not available in all patients. 
Dosing and treatment duration 
Patients were treated with Peg-IFN plus RBV according to the consensus statements in force 
during the respective treatment years [8, 9, 10, 11]. All subjects received Peg-IFN-α 2a 
180 μg/week or Peg-IFN-α 2b 1.5 μg/kg/week. Oral RBV was administered twice daily according 
to body weight in those individuals infected with HCV genotype 1/4 or in HIV/HCV-coinfected 
with genotype 2/3 in a manner that patients weighing <75 kg received 1000 mg/day and patients 
weighing ≥75 kg received 1200 mg/day, whereas monoinfected patients with HCV genotype 2 or 3 
infection received a flat dose of 800 mg of RBV. All patients with genotype 1 or 4, as well as 
HIV/HCV-coinfected individuals with genotype 2 or 3 and without RVR, received therapy during 
a period of 48 weeks. All the remaining subjects harboring genotype 2 or 3 were treated for 
24 weeks. 
Definition of response 
SVR was defined as undetectable HCV RNA levels 24 weeks after the scheduled end of 
therapy. RVR was defined as undetectable HCV RNA levels at TW4. Null response (NR) was 
assumed when the decline of HCV RNA levels at TW12 was <2 log10 IU/mL, without reaching 
undetectability. A ≥2 log10 IU/mL drop in HCV RNA levels at TW12 without presenting 
undetectable HCV RNA levels at TW12 or TW24 was defined as partial response. Viral 
breakthrough was assumed at reappearance of HCV RNA levels at any time during treatment after 
having reached undetectability. Relapse was considered when HCV RNA was undetectable at the 
end of therapy but detectable at TW24 post-treatment. 
Laboratory determinations and definition of advanced liver fibrosis 
Plasma HCV RNA was determined by a quantitative polymerase chain reaction assay 
according to the available technique at each center and treatment period (Cobas Amplicor HCV 
Monitor v2.0, Roche Diagnostic Systems Inc., Branchburg, NJ, USA; detection limit: 600 IU/mL; 
Cobas TaqMan AmpliPrep/TaqMan Test System, Roche Diagnostic Systems Inc., Pleasanton, CA, 
USA; detection limit: 10 IU/mL; Abbott M2000 RealTime System, Abbott Diagnostic, Chicago, 
IL, USA; detection limit 12 UI/mL). Plasma HIV RNA was determined by an in vitro nucleic acid 
amplification test for the quantitation of HIV-1 RNA in human plasma (Cobas AmpliPrep/Cobas 
TaqMan HIV-1 Test v2.0, Roche, Mannheim, Germany). The HCV genotype was determined 
using the Versant HCV Genotype 2.0 Auto LiPA or AutoBlot 3000H (Siemens, Frimley, 
Camberley, UK). IL28B rs12979860 was genotyped from frozen whole blood samples according 
to the manufacturer’s instructions using the LightMix® Kit IL28B (TIB Molbiol, GmbH, Berlin, 
Germany) or TaqMan® Genotyping Assay for rs12979860 (Applied Biosystems, Foster City, CA, 
USA) in a StepOnePlus™ Real-Time PCR System (Applied Biosystems). Advanced fibrosis was 
defined as F3 or F4 according to liver biopsy [12] or a liver stiffness measurement ≥9.5 kPa [13] if 
biopsy was not available. Liver stiffness was determined using transient elastometry (Fibroscan, 
Echosens, Paris, France). 
Statistical analyses 
Descriptive statistics were conducted for the study population. Quantitative variables were 
described by the median [interquartile range (IQR)], whereas qualitative variables were expressed 
as number [percentage; confidence interval (CI)]. Chi-square or Fisher’s test were used for 
comparison of qualitative variables. The Student’s t-test or the Mann–Whitney U-test was applied 
to compare quantitative variables. The primary outcome variable was SVR and was evaluated in 
an intention-to-treat approach, with missing values considered as failures. Afterwards, an on-
treatment approach, where patients who discontinued therapy due to adverse events, those who 
voluntarily dropped out, and those who were lost to follow-up were not included, was applied to 
identify predictors of SVR. Those variables associated with a p-value <0.2 in the univariate 
analysis were introduced in a multivariate logistic regression model to identify independent 
predictors of SVR. Data analysis was conducted using the SPSS statistical software package 
release 22.0 (IBM Corporation, Somers, NY, USA) and STATA 9.0 (StataCorp LP, College 
Station, TX, USA). 
  
Ethical issues 
All patients gave their written informed consent to participate in this study. Both the study 
design and performance complied with the Helsinki declaration and were approved by the local 
ethics committees of the participating study sites. 
Results 
Study population 
A total of 1046 patients fulfilled the inclusion criteria. Of these, 413 (39 %) were HIV-
coinfected. The median (IQR) age was 43 (38–48) years in the overall population and 771 (74 %) 
individuals were male. The proportion of patients with IL28B genotype CC among the 450 
subjects with this determination available was 43 % (195 patients). Two hundred and thirty-six 
(40 %) out of 595 patients with these data available showed advanced fibrosis. HIV RNA at 
baseline was undetectable in 175 (74 %) out of 236 HIV/HCV-coinfected patients in which these 
data were available. All infectious diseases units of the participant hospitals included HCV-
monoinfected and HIV/HCV-coinfected patients. The main baseline characteristics according to 
HIV coinfection are shown in Table 1. 
Table 1. Baseline characteristics of the study population according to human immunodeficiency (HIV) infection status 
Characteristic HIV (−), n = 633 HIV (+), n = 413 p-Value 
    
Male gender, n (%) 448 (71) 323 (78) 0.008 
Age (years)a 43 (38–50) 42 (38–46) 0.002 
Body mass index (kg/m2)a 26 (23–29) 23 (21–26) <0.001 
IL28B rs12979860 CC, n (%)b 86 (45) 109 (42) 0.534 
Injecting drug users, n (%) 266 (71) 339 (88) <0.001 
HCV genotype, n (%)c 
• 1: 325 (52) 201 (49) 0.001 
 - 1a 67 (21) 36 (18) <0.001* 
 - 1b 129 (40) 28 (14) 
 
 - 1 unknown 129 (40) 137 (68) 
 
• 2 33 (5) 5 (1) 
 
• 3 182 (29) 129 (32) 
 
• 4 80 (13) 71 (17) 
 
Plasma HCV RNA (log10 IU/mL)
a 6 (5.4–6.5) 6 (5.6–6.6) 0.171 
Advanced fibrosis, n (%)d 106 (45) 176 (61) <0.001 
Dose of ribavirin (mg/kg)a 14 (13–15) 15 (13–16) <0.001 
Use of pegylated interferon α2a, n (%)e 473 (85) 307 (81) 0.15 
    
 
aMedian (interquartile range); available in b450 and c1026 patients; *p-value for the comparison between HCV subtype 1; 
dfibrosis stage in biopsy F3 or F4 or liver stiffness ≥9.5 kPa if biopsy had not been carried out; eavailable in 594 individuals 
 
  
Response to therapy 
In an intention-to-treat analysis, SVR was obtained in 515 (49 %) patients, while RVR was 
achieved in 145 (38 %) out of 378 subjects who had a determination of the viral load in TW4. 
According to HIV coinfection, SVR was achieved in 341 (54 %, 95 % CI: 50–58 %) of the HCV-
monoinfected patients and in 174 (42 %, 95 % CI: 37–47 %) of the HIV/HCV-coinfected patients 
(p < 0.001). The corresponding figures for RVR were 86 (47 %, 95 % CI: 40–55 %) versus 59 
(30 %, 95 % CI: 24–37 %; p < 0.001). Seventy (40 %) of the HIV-infected patients who presented 
undetectable HIV RNA versus 24 (40 %) of those with detectable HIV RNA achieved SVR 
(p = 0.975). CD4 cell counts were 488 (702–374) cells/mL in those HIV-infected patients who 
achieved SVR versus 517 (390–704) cells/mL in those who did not (p = 0.583). Sixty-three (6 %) 
subjects had partial response, 129 (12 %) subjects showed NR, 26 (2 %) subjects showed 
virological breakthrough (VB), and 153 (15 %) patients relapsed. The rate of discontinuation due 
to adverse events was 6 %, accounting for 66 subjects. The number of individuals who voluntary 
dropped out was 64 (6 %), and 36 (3 %) subjects were lost to follow-up. Treatment outcomes 
within the HIV/HCV-coinfected and the HCV-monoinfected subpopulations are shown in Fig. 1a. 
In an on-treatment analysis, 515 (58 %) patients obtained SVR. According to HIV coinfection, 341 
(64 %, 95 % CI: 60–68 %) HCV-monoinfected and 174 (49 %, 95 % CI: 44–55 %) HIV/HCV-
coinfected patients presented SVR (p < 0.001). Figure 1b shows the treatment outcomes observed 




Fig. 1. Treatment outcomes of therapy with pegylated interferon plus ribavirin in an intention-to-treat analysis (a) and an 
on-treatment approach (b). Gray bars: HCV-monoinfected patients; white bars: HIV/HCV-coinfected; SVR: sustained 
virological response; RVR: rapid virological response; VB: virological breakthrough; AEs: adverse events 
The rates of SVR, RVR, partial response, NR, VB, and relapse according to HCV genotype 
and HIV infection in an intention-to-treat approach are depicted in Fig. 2. In an on-treatment 
analysis of the subpopulation of HCV genotype 1/4-infected individuals, the number of HCV-
monoinfected patients who obtained SVR was 188/338 (56 %, 95 % CI: 50–61 %) versus 82/225 
(36 %, 95 % CI: 30–43 %) of the HIV/HCV-coinfected patients (p < 0.001). Of the HCV genotype 
2/3-infected individuals, 149/183 (81 %, 95 % CI: 75–87 %) and 91/121 (75 %, 95 % CI: 66–
83 %) HCV-monoinfected and HIV/HCV-coinfected patients showed SVR, respectively 




Fig. 2. Intention-to-treat analysis of sustained virological response (a), rapid virological response (b), partial response (c), 
null response (d), virological breakthrough (e), and relapse (f) according to HCV genotype. Gray bars: HCV-monoinfected 





Fig. 3. Rates of sustained virological response (SVR) according to HCV 
genotype in an intention-to-treat analysis (a) and an on-treatment 
approach (b). Gray bars: HCV genotype 1; white bars: HCV genotype 4 
Predictors of response 
Given that HIV coinfection did not impact on the rates of SVR in HCV genotype 2/3-infected 
patients, subsequent analyses of possible confounders and interactions were limited to the HCV 
genotype 1/4-infected subpopulation. The results of the univariate and multivariate analyses are 
shown in Table 2. In a second multivariate analysis in which the variable advanced fibrosis was 
not included, absence of HIV coinfection was also independently associated with SVR [adjusted 
odds ratio (95 % CI): 1.927 (1.086–3.421); p = 0.025]. 
  
Table 2. Predictors of sustained virological response (SVR) in the univariate and multivariate analyses in the subpopulation 
of HCV genotype 1 or 4-infected patients (on-treatment analysis) 
Parameter SVR, n (%) 
Univariate  
p-value 
Adjusted OR  





  <42 127 (51) 0.194 1.004 (0.961–1.049) 0.842 
  ≥42 141 (45) 
   
Gender 
 Female 89 (57) 0.006 1.013 (0.479–2.141) 0.974 
 Male 181 (44) 
   
Advanced liver fibrosisb 
 No 108 (48) <0.001 2.127 (1.153–3.923) 0.016 
 Yes 55 (30) 
   
Baseline HCV RNA load (IU/mL)a 
  >600,000 136 (41) <0.001 0.527 (0.362–0.768) 0.001 
  ≤600,000 116 (63) 
   
HIV coinfection 
 Yes 82 (36) 
   
 No 188 (56) <0.001 2.087 (1.149–3.789) 0.016 
HCV genotype 
 1 205 (39) 0.005 0.631 (0.309–1.288) 0.206 
 4 65 (53) 
   
HCV subtype 
 1a 40 (46) 0.556 – – 
 1b 68 (50) 
   
 1 unknown 97 (44) 
   
Pegylated interferon 
 α2a 218 (50) 0.016 1.955 (0.941–4.063) 0.072 
 α2b 26 (35) 
   
IL28B genotype 
 CT/TT 48 (29) <0.001 0.269 (0.149–0.484) <0.001 
 CC 61 (64) 
   
CD4 cell count 
  <200 cells/mL 5 (50) 0.327 – – 
  ≥200 cells/mL 65 (35) 
   
     
 
*OR odds ratio; CI confidence interval 
aRepresented as a continuous variable in the multivariate analysis 







The results demonstrate that HIV coinfection negatively impacts on both SVR and viral 
kinetics in the first weeks of therapy with Peg-IFN plus RBV in subjects infected with HCV 
genotype 1 or 4. In patients with HCV genotype 2/3 infection, HIV does impair early viral kinetics 
during treatment, but, in spite of this fact, the rate of SVR is similar in HIV-coinfected and HIV-
uninfected patients. Although a negative impact of HIV on the outcome of HCV treatment with 
Peg-IFN plus RBV has been assumed for years, the present study shows this for the first time in a 
single population, followed with the same protocol care and with a large sample size. Also, this 
study shows that this effect is HCV genotype-dependent. 
 
Both HCV genotype 1 and 4-monoinfected patients showed significantly higher rates of SVR 
than those with HIV coinfection. The baseline characteristics were different for the two 
populations. Thus, the proportion of patients with advanced liver damage was higher in 
HIV/HCV-coinfected patients, which could potentially influence the response rates. However, in 
the multivariate analysis adjusted for advanced fibrosis, HIV was identified as an independent 
predictor of SVR along with well-known predictors such as IL28B genotype, advanced fibrosis, 
and baseline HCV RNA load. This observation is in accordance with the findings of a matched-
cohort study conducted in 208 patients published by Tural et al. [14]. In contrast to that study, 
where a monoinfected population was compared to a coinfected population derived from different 
clinics, in the herein described work, HCV-monoinfected, as well as HIV/HCV-coinfected patients 
were contributed by the same hospitals and followed by the same clinicians. In the study published 
by Tural et al., a lower rate of response in TW12, end of treatment, and SVR in the subset of HCV 
genotype 1-infected individuals was reported. In contrast to the findings of the present survey, in 
the above-stated study, a significant difference in the rates of RVR was not detected in this 
subpopulation. The rates of RVR in HCV genotype 1-infected patients are generally low 
disregarding the HIV infection status. Thus, it is likely that the low sample size resulted in a lack 
of statistical power, whereas the sample size of the present study overcame this limitation. 
Although genotypes 1 and 4 were commonly considered as comparable regarding response to dual 
therapy, it has become clear in the last several years that both response rates, as well as predictors 
of response, are different for these genotypes [2, 15], which could be confirmed with the 
observation reported. 
 
The analysis of the impact of HIV coinfection in the HCV genotype 2 or 3-infected 
subpopulation revealed a different effect to that observed for HCV genotypes 1 and 4. In this 
context, HIV-coinfection primarily impacted on the rates of RVR in HCV genotype 2 or 3-infected 
individuals, while the rates of SVR did not differ according to the coinfection status. This fact 
could be because the longer treatment duration in genotype 3-infected patients was made up for 
the slower viral kinetics. Again, this finding is in accordance with observations from other studies 
[14, 16]. Interestingly, the suppression of HIV RNA had no influence on the achievement of SVR 
in the HIV-infected subpopulation. This is somewhat surprising, since it has been demonstrated 
that HIV infection does impact on the HCV viral load, a potent predictor of SVR, but that this 
effect is not observed when HIV RNA is undetectable [17]. 
 
The impact of HIV infection reported in this study was observed in both an intention-to-treat, 
as well in an on-treatment approach. This is an important finding since, due to comorbidities and 
drug–drug interactions, coinfected patients might have been prone to develop adverse events 
leading to treatment discontinuations. The rates of voluntary dropouts were similar in both groups, 
suggesting a similar motivation of the patients to undergo treatment and making adherence 
unlikely to have accounted for the results of this study. There was, however, a significant 
difference in the rate of null response, which reflects a lower sensitivity to interferon in HIV-
coinfection, which is in accordance with the slower HCV RNA kinetics on treatment shown 
herein. 
  
In summary, we confirm in this direct comparison study that HIV coinfection is associated 
with lower SVR rates to Peg-IFN plus RBV in HCV genotype 1 or 4-infected patients. In contrast, 
there was no difference by HIV status in those patients with HCV genotypes 2 and 3, despite lower 
SVR rates in HIV-infected patients. Furthermore, it impacts on the viral kinetics during the first 
weeks of therapy in HCV genotype 2 or 3-infected individuals. This finding suggests that HIV 
coinfection may impair the sensitivity to interferon of HCV infection, which may have 
implications in explaining the immune response to HCV in HIV coinfection. 
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